Skip to main content
. Author manuscript; available in PMC: 2015 Dec 22.
Published in final edited form as: Nat Chem Biol. 2014 Sep 7;10(10):853–860. doi: 10.1038/nchembio.1629

Figure 6. Effects of ERK and PARP inhibitors on BRCA2-deficient cell survival.

Figure 6

a) Effect of SCH772984, VTX-11e, FR180204 and the PARP inhibitor olaparib on the survival of BRCA2-deficient and -proficient V-C8 hamster cells, following three-day exposure to each drug at the concentrations indicated. b) Human HEK239T cells were transfected with control or RAD51 siRNAs twice (day 0 and day 3) over a six day period. Cell extracts were prepared 12 hours and six days after the first transfection and analysed by Western blotting as indicated. Survival of HEK293T cells lacking RAD51 relative to control cells in the presence of SCH772984, VTX-11e and the PARP inhibitor olaparib, following six-day exposure to each drug at the concentrations indicated. Data represented are the means of two biological repeats and the standard deviations (SD).